Objective To evaluate the efficacy of treatment options for patients with recurrent ovarian cancer.Methods From 1990 to 2000, 54 patients with recurrent ovarian cancer primarily treated in Peking Union Medical College...Objective To evaluate the efficacy of treatment options for patients with recurrent ovarian cancer.Methods From 1990 to 2000, 54 patients with recurrent ovarian cancer primarily treated in Peking Union Medical College Hospital were selected and reviewed.All the clinical data related to the recurrent tumor were collected.Two-side P values for differences in survival were calculated by the Cox regression model.Results The platinum-free interval >6 months and the surgery followed by salvage chemotherapy prolonged survival time of the patients with recurrent ovarian cancer (95% CI=0.153-0.987, P=0.047; 95% CI=1.611-10.914, P=0.003, respectively).The increased number of chemotherapy cycles (> 10 months) offered some benefit on the survival (95% CI=0.110-1.090, P=0.070).The initiation of treatment and chemotherapy regiments failed to demonstrate an improvement in survival.Conclusion The treatment options for patients with recurrent ovarian cancer depend on the platinum-free-interval of the patients.A strategy of secondary surgical cytoreduction followed by salvage chemotherapy is suggested for the patients with platinum-sensitive disease.展开更多
Objective: To investigate the clinical value and application of ATP based bioluminescence tumor chemo-sensitivity assay (ATP-TCA) in the chemotherapy for ascites caused by recurrent ovarian cancer. Methods: More than ...Objective: To investigate the clinical value and application of ATP based bioluminescence tumor chemo-sensitivity assay (ATP-TCA) in the chemotherapy for ascites caused by recurrent ovarian cancer. Methods: More than 10 kinds of chemotherapeutic drugs or combinations were applied and 35 ascites specimens from recurrent ovarian cancer were analyzed by ATP-TCA. Sensitivity of chemotherapeutic drugs was assessed. After 2-4 chemotherapeutic cycles, clinical outcomes were analyzed, which were compared with those of 40 cases by empirical regimens. Results: 32 of 35 specimens were evaluated with an overall evaluation rate of 91%. The assay results suggested that chemo-naive patients responded to chemotherapeutic drugs with individualized profiles. The sensitivity rates of GEM, EPI, OXA, DDP, CBP, ADM, VP-16, CTX, NVB, 5-FU, PTX and TXT were 40%, 30%, 33%, 29%, 33%, 38%, 25%, 33%, 38%, 33%, 25% and 20%, respectively. While the sensitivity rates of combinations GEM + EPI, GEM + CBP, GEM + DDP, NVB + DDP, CTX + ADM + DDP, CTX + ADM, DDP + VP-16, OXA + 5-FU, VP-16 + IFO, PTX + DDP, TXT + CBP, VCR + CTX + MTX, DDP + CPT-11, OXA + CPT-11, and DTIC + CTX were 47%, 50%, 36%, 44%, 30%, 33%, 27%, 33%, 40%, 27%, 23%, 14%, 28%, 30% and 17%, respectively. In vitro results correlated well with clinical outcomes. Objective response rate (RR) in chemo-sensitivity-guided group was of significance compared with that in empirical-regimen-guided group. Conclusion: ATP-TCA is a choice for the screening of chemotherapeutic drugs against ascites caused by recurrent ovarian cancer with excellent sensitivity and reliability. ATP-TCA assay results correlate well with clinical outcomes, suggesting its clinical value in the management of difficult-to-manage therapeutic situations such as ascites in recurrent ovarian cancer.展开更多
Ovarian cancer has a poor outcome because it is usually detected at advanced tumor stages,and the majority of the patients develop disease relapse as a result of chemotherapy resistance.This most lethal gynecological ...Ovarian cancer has a poor outcome because it is usually detected at advanced tumor stages,and the majority of the patients develop disease relapse as a result of chemotherapy resistance.This most lethal gynecological malignancy metastasizes within the peritoneal fluid or ascites to pelvic and distal organs.In ovarian cancer progression and metastasis,small non-coding RNAs(ncRNAs),including long noncoding RNAs and microRNAs have been recognized as important regulators.Their dysregulation modulates gene expression and cellular signal pathways and can be detected in liquid biopsies.In this review,we provide an overview on circulating plasma and serum ncRNAs participating in tumor cell migration and invasion,and contributing to recurrence and metastasis of ovarian cancer.We will also discuss the development of potential,novel therapies using ncRNAs as target molecules or tumor markers for ovarian cancer.展开更多
文摘Objective To evaluate the efficacy of treatment options for patients with recurrent ovarian cancer.Methods From 1990 to 2000, 54 patients with recurrent ovarian cancer primarily treated in Peking Union Medical College Hospital were selected and reviewed.All the clinical data related to the recurrent tumor were collected.Two-side P values for differences in survival were calculated by the Cox regression model.Results The platinum-free interval >6 months and the surgery followed by salvage chemotherapy prolonged survival time of the patients with recurrent ovarian cancer (95% CI=0.153-0.987, P=0.047; 95% CI=1.611-10.914, P=0.003, respectively).The increased number of chemotherapy cycles (> 10 months) offered some benefit on the survival (95% CI=0.110-1.090, P=0.070).The initiation of treatment and chemotherapy regiments failed to demonstrate an improvement in survival.Conclusion The treatment options for patients with recurrent ovarian cancer depend on the platinum-free-interval of the patients.A strategy of secondary surgical cytoreduction followed by salvage chemotherapy is suggested for the patients with platinum-sensitive disease.
文摘Objective: To investigate the clinical value and application of ATP based bioluminescence tumor chemo-sensitivity assay (ATP-TCA) in the chemotherapy for ascites caused by recurrent ovarian cancer. Methods: More than 10 kinds of chemotherapeutic drugs or combinations were applied and 35 ascites specimens from recurrent ovarian cancer were analyzed by ATP-TCA. Sensitivity of chemotherapeutic drugs was assessed. After 2-4 chemotherapeutic cycles, clinical outcomes were analyzed, which were compared with those of 40 cases by empirical regimens. Results: 32 of 35 specimens were evaluated with an overall evaluation rate of 91%. The assay results suggested that chemo-naive patients responded to chemotherapeutic drugs with individualized profiles. The sensitivity rates of GEM, EPI, OXA, DDP, CBP, ADM, VP-16, CTX, NVB, 5-FU, PTX and TXT were 40%, 30%, 33%, 29%, 33%, 38%, 25%, 33%, 38%, 33%, 25% and 20%, respectively. While the sensitivity rates of combinations GEM + EPI, GEM + CBP, GEM + DDP, NVB + DDP, CTX + ADM + DDP, CTX + ADM, DDP + VP-16, OXA + 5-FU, VP-16 + IFO, PTX + DDP, TXT + CBP, VCR + CTX + MTX, DDP + CPT-11, OXA + CPT-11, and DTIC + CTX were 47%, 50%, 36%, 44%, 30%, 33%, 27%, 33%, 40%, 27%, 23%, 14%, 28%, 30% and 17%, respectively. In vitro results correlated well with clinical outcomes. Objective response rate (RR) in chemo-sensitivity-guided group was of significance compared with that in empirical-regimen-guided group. Conclusion: ATP-TCA is a choice for the screening of chemotherapeutic drugs against ascites caused by recurrent ovarian cancer with excellent sensitivity and reliability. ATP-TCA assay results correlate well with clinical outcomes, suggesting its clinical value in the management of difficult-to-manage therapeutic situations such as ascites in recurrent ovarian cancer.
文摘Ovarian cancer has a poor outcome because it is usually detected at advanced tumor stages,and the majority of the patients develop disease relapse as a result of chemotherapy resistance.This most lethal gynecological malignancy metastasizes within the peritoneal fluid or ascites to pelvic and distal organs.In ovarian cancer progression and metastasis,small non-coding RNAs(ncRNAs),including long noncoding RNAs and microRNAs have been recognized as important regulators.Their dysregulation modulates gene expression and cellular signal pathways and can be detected in liquid biopsies.In this review,we provide an overview on circulating plasma and serum ncRNAs participating in tumor cell migration and invasion,and contributing to recurrence and metastasis of ovarian cancer.We will also discuss the development of potential,novel therapies using ncRNAs as target molecules or tumor markers for ovarian cancer.
